Tonix opens Berkeley Heights HQ, expands NJ biotech footprint

The basics:

• Tonix Pharmaceuticals opens new Berkeley Heights headquarters at The Park
• Move follows FDA approval, launch of Tonmya — first new fibromyalgia treatment in 15 years
• Company doubles NJ office footprint to about 8,000 square feet, with more growth planned
• Tonix reported $190.1M in cash in Q3 2025; expects runway to fund operations through 2027

Tonix Pharmaceuticals celebrated its first day at The Park in Berkeley Heights with a ribbon-cutting ceremony, as the fully integrated biotechnology company committed to continuing its growth in New Jersey. 

It marks the latest milestone for the formerly Chatham-based drugmaker. In November 2025, Tonix brought Tonmya to market. Cleared by the U.S. Food & Drug Administration in August, the compound is the first new treatment for fibromyalgia in more than 15 years. 

“It’s deeply meaningful to me, to the Tonix family, to our investors, to all the patients who have participated in our studies and to the stakeholders — the headquarters represents more than a new address,” Dr. Seth Lederman, co-founder, chairman and CEO, said during the Friday ceremony. “It represents belief, perseverance and a shared commitment to delivering better treatments for people living with chronic pain and other complex disorders.” 

U.S. Rep. Tom Kean Jr., R-7th District, and Tonix board member Richard Bagger joined the commercial, clinical, regulatory and corporate teams that now call 200 Connell Drive home Jan. 30 to commemorate the move. 

Lederman said the company “pursues a simple but ambitious idea: Rigorous science guided by compassion for patients can be translated into real world solutions for conditions that are overlooked or mistreated.” 

Room to grow

Fibromyalgia is a chronic pain condition that affects more than 10 million U.S. adults, predominantly women. It has no cure. Symptoms include pain, fatigue, emotional and mental distress, and sleep problems. Lederman said Tonmya represents more than a new medicine, “but a new chapter. One rooted in thoughtful science and a deep respect for the lived experience of patients.” 

More broadly, Tonix’s work focuses on central nervous system disorders (CNS), immunology, immunoncology and infectious disease. The company reported $190.1 million in cash and cash equivalents in the third quarter of 2025, the most recent information available. As of Dec. 31, 2024, that figure stood at $98.8 million. The company said it expects its current cash runway to fund operations through 2027.  

Tonix Pharmaceuticals is just the latest company to join the roster at The Connell Co.’s 185-acre The Park, which is undergoing a $500 million overhaul. The work will transform the campus into a public-facing, live-work-play-stay destination in the heart of Union County — and located directly off Interstate 78.

Beyond the ultra-lux work resort environment the company has introduced, multifamily living options, retail and bespoke commercial concepts are also on their way.

For Tonix, the new office creates a shared space for collaboration as the company continues to expands its pipeline. “The site is designed to support growth not only in square footage, but also in ambition and impact. 

“Choosing Berkeley Heights was a deliberate decision. It was important for Tonix to continue our important work in our home state of New Jersey … because of its remarkable history of scientific breakthroughs, biotech leadership and the life sciences talent,” Lederman said.

He added that the new lease in Berkeley Heights reinforces Tonix’s commitment to contributing to that innovation economy.  

Beyond its New Jersey headquarters, Tonix also has offices in Texas, Canada and Ireland, as well as a 48,000-square-foot research and development center in Frederick, Md.

Tonix currently has a team of about 40 employees. And Chief Operating Officer Jessica Edgar Morris told NJBIZ the company is actively growing its ranks with new talent. The bigger footprint in Berkeley Heights – about 8,000 square feet and double its previous space – will help accommodate that acceleration.

“There’s a lot of talent in this area,” she said, noting Tonix didn’t even consider leaving the state when its Chatham lease was up. “We know what it’s like to be in another location,” Morris said, adding New Jersey keeps the team central to its other outposts along the East Coast, along with New York City.

New frontiers

Kean described Tonix’s move to Berkeley Heights as helping to embellish an already flourishing ecosystem as well as an enormous opportunity.

“This district has the most life sciences pharmaceutical companies of any congressional district in the county,” he told NJBIZ of the territory he represents. “And so now we’ve added one more headquarters there.” 

These kinds of investments and endorsements allow the Garden State “to continue to be on the cutting edge of innovation. And we can continue to build on both the legacy of where we have been, but also the future, which is ensuring that we are finding solutions that make worldwide differences.” 

“The fact that they chose to come here in New Jersey—it’s an important testament to the economic growth and the opportunity for the future,” Kean said. 

Welcoming Tonix during his prepared remarks, Kean commended the team for its commitment. He said the company understands the importance of solving people’s problems so they can focus on living, underscoring Tonmya as proof of concept.

Describing the partnership between the region and Tonix as strong, Kean said that trajectory will persist, “because of the people who are in this room, but also people who know the importance of focusing on non-opioid relief. Because we understand that that’s where the next level of chronic pain belief is.”